DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1768 cancer in postmenopausal women previously untreated with
endocrine therapy: A multinational, double-blind, randomized
trial. J Clin Oncol, 2004a, 22:1605–1613.
Howell SJ, Johnston SR, Howell A. The use of selective estrogen
receptor modulators and selective estrogen receptor
down-regulators in breast cancer. Best Pract Res Clin
Endocrinol Metab, 2004b, 18:47–66.
Huggins C, Hodges CV. Studies on prostatic cancer: I. The
effects of castration, of estrogen, and of androgen injection on
serum phosphatases in metastatic carcinoma of the prostate.
McLeod DG. Tolerability of nonsteroidal antiandrogens in the
treatment of advanced prostate cancer. Oncologist, 1997,
2:18–27.
Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance
of intratumoral androgens in metastatic prostate cancer: A
mechanism for castration-resistant tumor growth. Cancer Res,
2008, 68:4447–4454.
Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of
letrozole versus tamoxifen as first-line therapy of advanced
breast cancer in postmenopausal women: Analysis of survival
Cancer Res, 1941, 1:293–297.
and update of efficacy from the International Letrozole Breast
Huggins C, Stevens RE Jr, Hodges CV. Studies on prostatic cancer:
Cancer Group. J Clin Oncol, 2003, 21:2101–2109.
II. The effects of castration on advanced carcinoma of the
prostate gland. Arch Surg, 1941, 43:209–233.
Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of
ERBB2 by oestrogen receptor-PAX2 determines response to
tamoxifen. Nature, 2008, 456:663–666.
Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of
LHRH analogue (Zoladex) with orchiectomy in patients with
metastatic prostatic carcinoma. Br J Urol, 1991, 67:502–508.
Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular
disease during androgen deprivation therapy for prostate
cancer. J Clin Oncol, 2006, 24:4448–4456.
Kim J, Tang JY, Gong R, et al. Intraconazole, a commonly used
antifungal that inhibits Hedgehog pathway activity and growth.
Cell, 2010, 17:388–399.
Klijn JG, Beex LV, Mauriac L, et al. Combined treatment with
buserelin and tamoxifen in premenopausal metastatic breast
cancer: A randomized study. J Natl Cancer Inst, 2000,
92:903–911.
Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and
safety of degarelix: A 12-month, comparative, randomized,
open-label, parallel-group phase III study in patients with
prostate cancer. BJU Int, 2008, 102:1531–1538.
Köberle D, Thürlimann B. Anastrozole: Pharmacological and
clinical profile in postmenopausal women with breast cancer.
Expert Rev Anticancer Ther, 2001, 1:169–176.
Kuhn JM, Billebaud T, Navratil H, et al. Prevention of the transient
adverse effects of a gonadotropin-releasing hormone analogue
(buserelin) in metastatic prostatic carcinoma by
administration of an antiandrogen (nilutamide). N Engl J Med,
1989, 321:413–418.
Landström M, Damber JE, Bergh A. Estrogen treatment postpones
the castration-induced dedifferentiation of Dunning R3327-PAP
prostatic adenocarcinoma. Prostate, 1994, 25: 10–18.
Limonta P, Montagnani Marelli M, Moretti RM. LHRH analogues
as anticancer agents: Pituitary and extrapituitary sites of
action. Expert Opin Investig Drugs, 2001, 10:709–720.
Lønning PE, Geisler J, Krag LE, et al. Effects of exemestane
administered for 2 years versus placebo on bone mineral density,
bone biomarkers, and plasma lipids in patients with surgically
resected early breast cancer. J Clin Oncol, 2005,
23:5126–5137.
Luo S, Martel C, Chen C, et al. Daily dosing with flutamide or
Casodex exerts maximal antiandrogenic activity. Urology,
1997, 50:913–919.
McCormack P, Sapunar F. Pharmacokinetic profile of the fulvestrant
loading dose regimen in postmenopausal women with
hormone receptor-positive advanced breast cancer. Cancer,
2008, 8:347–351.
Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular
adverse events during adjuvant endocrine therapy for early
breast cancer using letrozole or tamoxifen: Safety analysis of
BIG 1-98 trial. J Clin Oncol, 2007, 25:5715–5722.
Moy B, Goss PE. Estrogen receptor pathway: Resistance to
endocrine therapy and new therapeutic approaches. Clin
Cancer Res, 2006, 12:4790–4793.
Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing
exemestane with tamoxifen as first-line hormonal treatment
of metastatic breast cancer in postmenopausal women:
The European Organisation for Research and Treatment of
Cancer Breast Cancer Cooperative Group. J Clin Oncol, 2008,
26:4883–4890.
Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and
estramustine compared with mitoxantrone and prednisone for
advanced refractory prostate cancer. N Engl J Med, 2004,
351:1513–1520.
Pfitzenmeyer P, Foucher P, Piard F, et al. Nilutamide pneumonitis:
A report on eight patients. Thorax, 1992, 47: 622–627.
Robertson JF. Estrogen receptor downregulators: New antihormonal
therapy for advanced breast cancer. Clin Ther, 2002,
24:A17–A30.
Saad F, Gleason DM, Murray R, et al. A randomized, placebocontrolled
trial of zoledronic acid in patients with hormonerefractory
metastatic prostate carcinoma. J Natl Cancer Inst,
2002, 94:1458–1468.
Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review
and meta-analysis of monotherapy compared with combined
androgen blockade for patients with advanced prostate carcinoma.
Cancer, 2002, 95:361–376.
Saylor PJ, Smith MR. Metabolic complications of androgen deprivation
therapy for prostate cancer. J Urol, 2009, 181:
1998–2008.
Schally AV, Coy DH, Arimura A. LH-RH agonists and antagonists.
Int J Gynaecol Obstet, 1980, 18:318–324.
Scherr D, Pitts WRJ, Vaugh EDJ. Diethylstilbesterol revisited:
Androgen deprivation, osteoporosis and prostate cancer.
J Urol, 2002, 167:535–538.
Schmitt B, Bennett C, Seidenfeld J. Maximal androgen blockade
for advanced prostate cancer. Cochrane Database Syst Rev,
1999, 2:CD001526.
Schroder FH, Collette L, de Reijke TM, Whelan P. Prostate cancer
treated by anti-androgens: Is sexual function preserved?
Br J Cancer, 1999, 82:283–290.
Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy
androgen suppression in men with advanced prostate cancer:
A systematic review and meta-analysis. Ann Intern Med, 2000,
132:566–577.
SECTION VIII
CHEMOTHERAPY OF NEOPLASTIC DISEASES